Tuesday, September 12, 2017

Liver Cancer After Treatment For Hepatitis C: Achieving SVR Reduced HCC Risk by 71%

In case you missed it 

Full Text Article Provided Jules Levin Executive Director of  NATAP

HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma
Jnl of Hepatology Sept 5 2017 - George N. Ioannou BMBCh MS1,2, Pamela K. Green PhD2, Kristin Berry PhD2.

Jules: and cirrhosis increases risk of HCC SO Treat Early

"Most HCV-infected patients in the United States will undergo DAA-based antiviral treatment in the next few years and the vast majority of them will achieve SVR. Our results suggest that DAA-induced SVR is associated with a 71% reduction in HCC risk (AHR 0.29, 95% CI 0.23-0.37) compared to treatment failure. The reduction in HCC risk associated with SVR was similar irrespective of whether SVR was achieved by DAA-ONLY, DAA+IFN or IFN-ONLY regimens. This suggests that eradication of HCV reduces HCC risk independently of how it is achieved. In contrast to prior reports that suggested an increased HCC risk in patients treated with DAAs[[3], [7]], we found that receipt of DAA-ONLY antiviral treatment was not associated with increased risk of HCC when compared to receipt of IFN-ONLY antiviral treatment.....We found no evidence that treatment with DAAs was associated with increased risk of HCC compared to treatment with IFN.

On This Blog
View an index of links to current data investigating the possible risk of developing liver cancer (hepatocellular carcinoma, or HCC) during and after direct-acting antiviral therapy in patients with hepatitis C.

No comments:

Post a Comment